Feb 5 |
Immix Biopharma Announces Proposed Public Offering of Common Stock
|
Jan 24 |
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
|
Jan 11 |
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
|
Jan 4 |
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
|
Dec 18 |
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
|
Dec 15 |
Insider Spends US$267k Buying More Shares In Immix Biopharma
|
Dec 11 |
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
|
Dec 3 |
Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status
|
Nov 30 |
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
|
Nov 28 |
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
|